Goldman Sachs
MPLT

Goldman Sachs’s MapLight Therapeutics MPLT Stock Holding History

Goldman Sachs’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.8M Sell
1,948,312
-46,561
-2% -$1.34M 0.01% 1520
2026
Q1 		$40.6M Buy
1,994,873
+57,705
+3% +$1.03M ﹤0.01% 1745
2025
Q4 		$34M Buy
+1,937,168
New +$32.5M ﹤0.01% 1834

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs's MPLT Position: Q2 2026 in Review

Goldman Sachs reduced its MapLight Therapeutics (MPLT) stake by 2.3% in Q2 2026, selling an estimated $1.34M and leaving 1,948,312 shares worth $69.8M. The position accounts for 0.01% of the portfolio, ranked #1520.

Goldman Sachs first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Goldman Sachs held 1,948,312 shares of MapLight Therapeutics worth $69.8M as of Q2 2026.
  • Goldman Sachs sold 46,561 MapLight Therapeutics shares in Q2 2026, an estimated $1.34M.
  • MapLight Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1520 holding.
  • Goldman Sachs first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 105 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.